C. Oliver Kappe,
Professor and Scientific Director, Center for Continuous Flow Synthesis and Processing,
University of Graz
C. Oliver Kappe is Professor of Chemistry at the University of Graz (Austria) and Scientific Director of the Center for Continuous Flow Synthesis and Processing (CC FLOW) at the Research Center Pharmaceutical Engineering GmbH (RCPE). He received his diploma (1989) and his doctoral (1992) degrees in organic chemistry from the University of Graz where he worked with Gert Kollenz on cycloaddition and rearrangement reactions of acylketenes. After periods of postdoctoral research work on reactive intermediates and matrix isolation spectroscopy with Curt Wentrup at the University of Queensland in Brisbane, Australia (1993-1994) and on synthetic methodology/alkaloid synthesis with Albert Padwa at Emory University in Atlanta, USA (1994-1996), he moved back to the University of Graz in 1996 to start his independent academic career. He obtained his „Habilitation“ in 1998 in organic chemistry and was appointed Associate Professor in 2000. Since 2011 he is Professor for „Technology of Organic Synthesis“ (Organische Synthesetechnologie) at the Institute of Chemistry at the University of Graz. He has spent time as visiting scientist/professor at e.g. the Scripps Research Institute (La Jolla, USA, K. Barry Sharpless, 2003), the Toyko Institute of Technology (Toyko, Japan, T. Takahashi, 2008), the Sanford-Burnham Institute for Medical Research (Orlando, USA, 2010) and the Federal University of Rio de Janeiro (Rio de Janeiro, Brazil, 2013-2015).
Professor Kappe has an extensive general experience and a 25 year track record in synthetic and physical organic chemistry, process intensification using batch microwave technology and flow chemistry/microreaction technology, communicated in ~400 scientific publications (Research ID, WoS h-Index 72). For the past decade the focus of his research has been directed towards flow chemistry/microreaction technology, encompassing a wide variety of synthetic transformations and experimental techniques. His research group is actively involved in projects dealing with API synthesis and manufacturing, employing a number of different enabling and process intensification technologies. For his innovative work in microwave chemistry he received the 2004 Prous Science Award from the European Federation for Medicinal Chemistry and the 2010 100.000 € Houska Prize in addition to a number of other awards. In 2015 he was named Fellow of the Royal Society of Chemistry.
C. Oliver Kappe is the Founding Editor and current Editor-in-Chief of the Journal of Flow Chemistry (Springer) and a board member of the Flow Chemistry Society. In addition he has been an Editor of the Journal QSAR and Combinatorial Sciences (Wiley-VCH, 2003-2007) and has served/serves on the Editorial/Advisory Boards of Green Chemistry, Reaction Chemistry & Engineering (RSC), Current Opinion in Green and Sustainable Chemistry (Elsevier), ChemMedChem and ChemSusChem (Wiley-VCH), Journal of Combinatorial Chemistry (ACS), Molecular Diversity (Springer), Journal of Heterocyclic Chemistry (Wiley-VCH) and a number of other journals. For several years he has been teaching courses on flow chemistry for Scientific Update.
From Flow Chemistry in the Lab Towards Industrial Implementation on Scale – Case Studies on Continuous API Synthesis
Tuesday, 8 October 2019 at 14:30
Add to Calendar ▼2019-10-08 14:30:002019-10-08 15:30:00Europe/LondonFrom Flow Chemistry in the Lab Towards Industrial Implementation on Scale – Case Studies on Continuous API SynthesisMicrofluidics and Flow Chemistry 2019 in Coronado Island, CaliforniaCoronado Island, CaliforniaSELECTBIOenquiries@selectbiosciences.com
Continuous flow processes form the basis of the petrochemical and bulk chemicals industry where strong competition, stringent environmental and safety regulations, and low profit margins drive the need for highly performing, cost effective, safe and atom efficient chemical operations. In contrast to the commodity chemical industry, however, the fine chemical industry primarily relies on its existing infrastructure of multipurpose batch or semi-batch reactors. Fine chemicals, such as drug substances and active pharmaceutical ingredients (APIs), are generally considerably more complex than commodity chemicals and usually require numerous, widely diverse reaction steps for their synthesis. These requirements generally make versatile and reconfigurable multipurpose batch reactors the technology of choice for their preparation. However, the advantages of continuous flow processing are increasingly being appreciated also by the pharmaceutical industry and, thus, a growing number of scientists, from research chemists in academia to process chemists and chemical engineers in pharmaceutical companies, are now starting to employ continuous flow technologies on a more routine basis. In this lecture, contributions from our research group in the field of continuous flow processing will be highlighted. Emphasis will be given to highly atom efficient and process intensified chemical transformations useful for the synthesis of APIs or key intermediates that are often too hazardous to be executed in a batch reactor. These involve azide, diazomethane and nitration chemistry, selective precious metal-free olefin and nitrogroup reductions, oxidation reactions involving pure oxygen, and flow photochemistry applications. Special emphasis will be given to the scalability issues and industrial collaboration with both pharma companies and CMOs and equipment/technology providers.
Add to Calendar ▼2019-10-08 00:00:002019-10-09 00:00:00Europe/LondonMicrofluidics and Flow Chemistry 2019Microfluidics and Flow Chemistry 2019 in Coronado Island, CaliforniaCoronado Island, CaliforniaSELECTBIOenquiries@selectbiosciences.com
Add to Calendar ▼2019-10-08 14:30:002019-10-08 15:30:00Europe/LondonFrom Flow Chemistry in the Lab Towards Industrial Implementation on Scale – Case Studies on Continuous API SynthesisMicrofluidics and Flow Chemistry 2019 in Coronado Island, CaliforniaCoronado Island, CaliforniaSELECTBIOenquiries@selectbiosciences.com
